About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:4847559
Allelic
Composition
Nphs2tm1Antc/Nphs2tm3.1Antc
Tg(CAG-cre/Esr1*)86Lbgn/0
Genetic
Background
involves: 129 * C57BL/6 * DBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nphs2tm1Antc mutation (0 available); any Nphs2 mutation (3 available)
Nphs2tm3.1Antc mutation (0 available); any Nphs2 mutation (3 available)
Tg(CAG-cre/Esr1*)86Lbgn mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice die 11 weeks after tamoxifen treatment (J:166320)
• mice die 11 weeks after tamoxifen treatment (J:166320)

renal/urinary system
• after 4 weeks of tamoxifen treatment, mice develop nonselective proteinuria compared with control mice (J:166320)
• after 4 weeks of tamoxifen treatment, mice develop nonselective proteinuria compared with control mice (J:166320)
• after 10 days of tamoxifen treatment (J:166320)
• after 2 weeks of nursing from mice fed tamoxifen (J:166320)
• after 2 weeks of nursing from mice fed tamoxifen (J:166320)
• after 10 days of tamoxifen treatment (J:166320)
• after 9 weeks, tamoxifen-treated mice exhibit progressive tubular injury with basement membrane thickening and interstitial fibrosis unlike similarly treated wild-type mice (J:166320)
• after 9 weeks, tamoxifen-treated mice exhibit progressive tubular injury with basement membrane thickening and interstitial fibrosis unlike similarly treated wild-type mice (J:166320)
• tamoxifen-treated mice exhibit focal effacement at 1 and 2 weeks then diffuse effacement at 4 weeks unlike similarly treated wild-type mice (J:166320)
• tamoxifen-treated mice exhibit focal effacement at 1 and 2 weeks then diffuse effacement at 4 weeks unlike similarly treated wild-type mice (J:166320)
• after 2 weeks of tamoxifen treatment, mice exhibit podocyte hypertrophy compared with similarly treated control mice (J:166320)
• after 2 weeks of tamoxifen treatment, mice exhibit podocyte hypertrophy compared with similarly treated control mice (J:166320)
• after 4 weeks, tamoxifen-treated mice exhibit glomerular pseudocrescents in some glomeruli unlike in similarly treated control mice (J:166320)
• after 4 weeks, tamoxifen-treated mice exhibit glomerular pseudocrescents in some glomeruli unlike in similarly treated control mice (J:166320)
• mice nursed by dams fed tamoxifen exhibit lesions of mesangial proliferation compared with similarly treated controls (J:166320)
• mice nursed by dams fed tamoxifen exhibit lesions of mesangial proliferation compared with similarly treated controls (J:166320)
• after 2 weeks of tamoxifen treatment, mice exhibit minimal mesangial matrix expansion compared with similarly treated control mice (J:166320)
• after 2 weeks of tamoxifen treatment, mice exhibit minimal mesangial matrix expansion compared with similarly treated control mice (J:166320)
• after 4 weeks of tamoxifen treatment, mice exhibit focal segmental glomerulosclerosis in many glomeruli with varying severity unlike in similarly treated control mice (J:166320)
• mice nursed by dams fed tamoxifen exhibit lesions of focal segmental glomerulosclerosis unlike similarly treated control mice (J:166320)
• glomerulosclerosis worsens by 6 weeks of tamoxifen treatment (J:166320)
• at or near death, tamoxifen-treated mice exhibit global scelrosis (J:166320)
• after 4 weeks of tamoxifen treatment, mice exhibit focal segmental glomerulosclerosis in many glomeruli with varying severity unlike in similarly treated control mice (J:166320)
• mice nursed by dams fed tamoxifen exhibit lesions of focal segmental glomerulosclerosis unlike similarly treated control mice (J:166320)
• glomerulosclerosis worsens by 6 weeks of tamoxifen treatment (J:166320)
• at or near death, tamoxifen-treated mice exhibit global scelrosis (J:166320)
• after 9 weeks in tamoxifen-treated mice (J:166320)
• after 9 weeks in tamoxifen-treated mice (J:166320)
• tamoxifen-treated mice exhibit tubulointerstitial injury with diffuse tubular dilation, tubular atrophy and necrosis, and proteinaceous casts unlike in similarly treated control mice (J:166320)
• tamoxifen-treated mice exhibit tubulointerstitial injury with diffuse tubular dilation, tubular atrophy and necrosis, and proteinaceous casts unlike in similarly treated control mice (J:166320)
• in tamoxifen-treated mice (J:166320)
• in tamoxifen-treated mice (J:166320)
• in tamoxifen-treated mice (J:166320)
• in tamoxifen-treated mice (J:166320)
• in tamoxifen-treated mice (J:166320)
• in tamoxifen-treated mice (J:166320)
• in tamoxifen-treated mice (J:166320)
• in tamoxifen-treated mice (J:166320)

homeostasis/metabolism
• after 6 weeks of tamoxifen treatment (J:166320)
• after 6 weeks of tamoxifen treatment (J:166320)
• after 6 weeks of tamoxifen treatment (J:166320)
• after 6 weeks of tamoxifen treatment (J:166320)
• after 4 weeks of tamoxifen treatment (J:166320)
• after 4 weeks of tamoxifen treatment (J:166320)
• after 4 weeks of tamoxifen treatment, mice develop nonselective proteinuria compared with control mice (J:166320)
• after 4 weeks of tamoxifen treatment, mice develop nonselective proteinuria compared with control mice (J:166320)
• after 10 days of tamoxifen treatment (J:166320)
• after 2 weeks of nursing from mice fed tamoxifen (J:166320)
• after 10 days of tamoxifen treatment (J:166320)
• after 2 weeks of nursing from mice fed tamoxifen (J:166320)

cardiovascular system
• modestly after 4 weeks of tamoxifen treatment (J:166320)
• modestly after 4 weeks of tamoxifen treatment (J:166320)

Mouse Models of Human Disease
OMIM ID Ref(s)
Nephrotic Syndrome, Type 2; NPHS2 600995 J:166320


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/02/2016
MGI 6.02
The Jackson Laboratory